Division of Basic Medical Sciences, St. George's University of London, Cranmer Terrace, Tooting, London, SW17 0RE United Kingdom.
J Clin Endocrinol Metab. 2011 Mar;96(3):E427-35. doi: 10.1210/jc.2010-2060. Epub 2011 Jan 5.
Hyperinsulinemia in polycystic ovary syndrome is widely treated with the insulin sensitizer metformin, which, in addition to its systemic effects, directly affects the ovarian insulin-stimulated steroidogenesis pathway.
Our aim was to investigate the interaction of metformin with the other insulin-stimulated ovarian pathway, namely that leading to glucose uptake.
Human granulosa-luteal cells were cultured with metformin (10(-7) M), insulin (10 ng/ml) or metformin and insulin (met + ins) combined. Insulin receptor (IR) involvement was assessed by culture with an (anti)-insulin receptor (IR) antibody.
The effect of metformin on insulin-receptor substrate proteins 1 and 2 (IRS-1 and -2) mRNA and protein expression was determined. The KGN granulosa-cell line was used to investigate the effect of insulin and metformin on Akt activation and glucose transporter-4 (Glut-4) expression. Glut-4 translocation from the cytosol to the membrane was determined in cytoplasmic and membrane-enriched fractions of protein lysates.
IRS-1 mRNA and protein increased with all treatments. In contrast, basal IRS-2 mRNA levels were barely detectable, but transcription was up-regulated by metformin. The anti-IR antibody reduced treatment-stimulated IRS-1 to basal levels and IRS-2 expression to an even greater extent than IRS-1, showing greater dependence on the IR than IRS-1. Metformin in the presence of insulin activated Akt and this was dependent on phosphoinositide-3 kinase, as was translocation of Glut-4 to the membrane. Metformin was able to substantially enhance the insulin-stimulated translocation of Glut-4 transporters from the cytosol to the membrane.
This net increase in Glut-4 transporters in the plasma membrane has the potential to increase glucose uptake and metabolism by granulosa cells of the insulin-resistant polycystic ovary, thereby facilitating follicle growth.
多囊卵巢综合征中的高胰岛素血症通常采用胰岛素增敏剂二甲双胍进行治疗,除了全身作用外,二甲双胍还直接影响卵巢胰岛素刺激的甾体生成途径。
我们的目的是研究二甲双胍与其他胰岛素刺激的卵巢途径(即葡萄糖摄取途径)的相互作用。
用二甲双胍(10(-7)M)、胰岛素(10ng/ml)或二甲双胍和胰岛素(met+ins)联合培养人颗粒黄体细胞。通过用(抗)胰岛素受体(IR)抗体培养来评估胰岛素受体(IR)的参与。
测定二甲双胍对胰岛素受体底物蛋白 1 和 2(IRS-1 和 -2)mRNA 和蛋白表达的影响。使用 KGN 颗粒细胞系研究胰岛素和二甲双胍对 Akt 激活和葡萄糖转运蛋白 4(Glut-4)表达的影响。通过细胞质和富含膜的蛋白裂解物中的细胞质和膜蛋白转移来确定 Glut-4 从细胞质到膜的易位。
IRS-1mRNA 和蛋白均随所有处理而增加。相反,基础 IRS-2mRNA 水平几乎检测不到,但二甲双胍可上调转录。抗 IR 抗体将治疗刺激的 IRS-1 降低至基础水平,并且 IRS-2 的表达比 IRS-1 更为显著,表明对 IR 的依赖性大于 IRS-1。胰岛素存在时的二甲双胍激活 Akt,这依赖于磷酸肌醇 3 激酶,而 Glut-4 向膜的易位也是如此。二甲双胍能够显著增强胰岛素刺激的 Glut-4 转运蛋白从细胞质向膜的易位。
这种质膜中 Glut-4 转运蛋白的净增加有可能增加胰岛素抵抗多囊卵巢颗粒细胞的葡萄糖摄取和代谢,从而促进卵泡生长。